In:
Cancer, Wiley, Vol. 122, No. 12 ( 2016-06-15), p. 1871-1879
Abstract:
This is the first study to show a link between RAS ‐mutant myeloid malignancies and clinical responses to mitogen‐activated protein kinase kinase inhibitor therapy. These data highlight the importance of the RAS/RAF/mitogen‐activated protein kinase pathway in leukemogenesis and support further study of trametinib in patients with RAS ‐mutant myeloid malignancies.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v122.12
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink